Last reviewed · How we verify
NCT04738903
Q Value Customized Versus Wavefront Optimized Ablation in Femtosecond Laser-Assisted LASIK
NA trial testing Femtosecond laser assisted LASIK eye surgery in Patients With Myopic Spherical Equivalent up to -12 Diopters in 40 participants. Completed in 30 June 2021.
30 June 2021
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 June 2020 |
| Primary completion | 30 June 2021 |
| Estimated completion | 30 June 2021 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Femtosecond laser assisted LASIK eye surgery
Conditions studied
- Patients With Myopic Spherical Equivalent up to -12 Diopters — all drugs for Patients With Myopic Spherical Equivalent up to -12 Diopters →
Sponsor
Assiut University
Who can join
18 and older, any sex, with Patients With Myopic Spherical Equivalent up to -12 Diopters. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Corneal asphericity is expressed numerically as the "Q-value". A minus value means that corneal curvature flattens towards the periphery and the cornea is prolate in shape, but when the curvature steepens towards the periphery, the cornea is oblate in shape and has a positive Q-value. The current study evaluates the effect of LASIK eye surgery on corneal asphericity by comparing 2 software treatment platforms; the Q value customized ablation versus the conventional Wave-front optimized ablation in a fellow eye study pattern.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Q-value customized versus wavefront-optimized ablation in femtosecond laser-assisted LASIK for myopia and myopic astigmatism: a prospective contralateral comparative study.
Mostafa MM, Abdelmotaal H, Abdelazeem K, Goda I, et al · · 2022 · cited 1× · PMID 36320050 · DOI 10.1186/s40662-022-00312-3
Verify or expand the search:
- PubMed search for NCT04738903
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04738903 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 20 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04738903.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing